TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37821170

Group type: EXPERIMENTAL
Intervention: Flurpiridaz F-18 PET myocardial perfusion imaging
Number of subjects: 730

Group type: COMPARATOR
Intervention: Tc-99m-labeled SPECT
Number of subjects: 730
Study: 37821242

Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy (MDT) and 6 months of androgen deprivation therapy (ADT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Elective nodal pelvic radiotherapy (ENRT) [25 × 1.8 Gy] with MDT and 6 months of ADT
Number of subjects: 196
Study: 37821342

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at ZT8
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at ZT8
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Afternoon group (patients)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Morning group (patients)
Number of subjects: 2
Study: 37821461

Group type: EXPERIMENTAL
Intervention: Antipsychotics plus metformin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Antipsychotics alone
Number of subjects: 72
Study: 37821472

Group type: EXPERIMENTAL
Intervention: Latency-reversing agent vorinostat, ChAdV63.HIVconsv and MVA.HIVconsv vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 0
Study: 37821876

Group type: EXPERIMENTAL
Intervention: App-based dietary intervention over 12 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 93
Study: 37821913

Group type: EXPERIMENTAL
Intervention: Multimodal intervention based on Cognitive Behavior Therapy
Number of subjects: 880
Study: 37821924

Group type: EXPERIMENTAL
Intervention: 8-week co-produced web-based educational programme consisting of 6 modules
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 37821950

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measuring skeletal muscle regional tissue oxygenation (rSO2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Basal and maximal skeletal muscle rSO2 measurements
Number of subjects: 20
Study: 37821968

Group type: EXPERIMENTAL
Intervention: Central venous oxygen saturation (ScvO2)-based goal-directed therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fluid loading-based goal-directed therapy
Number of subjects: 0
Study: 37821994

Group type: EXPERIMENTAL
Intervention: Preoperative multidisciplinary team (MDT) meetings
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Preoperative screening as usual
Number of subjects: 1200
Study: 37822243

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight fucoidan (LMF) as a supplement to therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 0
Study: 37822567

Group type: EXPERIMENTAL
Intervention: Decompressive laparotomy (DL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Decompressive craniectomy (DC)
Number of subjects: 100
Study: 37822710

Group type: EXPERIMENTAL
Intervention: Exercise (60- to 75-min daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 22
Study: 37822872

Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Log-transformed inflammatory biomarkers IL-6 and hsCRP
Number of subjects: 6209
Study: 37823031

Group type: EXPERIMENTAL
Intervention: TransCon CNP 100 μg CNP/kg/week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 37823034

Group type: EXPERIMENTAL
Intervention: TV-46046 (120 mg/0.3 mL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Depo-subQ Provera 104 (104 mg/0.65 mL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Diluted TV-46046 (60 mg/0.3 mL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: TV-46046 placebo (0.3 mL)
Number of subjects: 27
Study: 37823469

Group type: EXPERIMENTAL
Intervention: Systemic immunosuppression (glucocorticoids or mycophenolate mofetil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucocorticoid treatment
Number of subjects: 0
Study: 37823562

Group type: EXPERIMENTAL
Intervention: Music enrichment program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Playdate control
Number of subjects: 32
Study: 37823722

Group type: EXPERIMENTAL
Intervention: Fingolimod treatment
Number of subjects: 324

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 324
Study: 37823729

Group type: EXPERIMENTAL
Intervention: Ultrasonographic measurements of diaphragmatic excursion (DE) and thickening fraction (TF) before anaesthesia induction (T0), 1 h postoperatively (T1), and 24 h postoperatively (T2)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ultrasonographic measurements of DE T2 /DE T0 and TF T2 /TF T0
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis of DE T2 /DE T0
Number of subjects: 74
Study: 37823892

Group type: EXPERIMENTAL
Intervention: CamAPS FX Hybrid Closed-Loop with Ultra-Rapid Lispro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Lispro
Number of subjects: 0
Study: 37823971

Group type: COMPARATOR
Intervention: Heparin (5000 IU/ml)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (8.4%)
Number of subjects: 426
Study: 37824038

Group type: EXPERIMENTAL
Intervention: Compression sonography of the internal jugular vein (IJVP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Invasive measures of central venous pressure (CVP)
Number of subjects: 10
Study: 37824131

Group type: EXPERIMENTAL
Intervention: Intratumoral GLA-SE (5 μg and 10 μg for 8 weekly doses) with concurrent radiotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intratumoral GLA-SE with concurrent radiotherapy
Number of subjects: 12
Study: 37824137

Group type: COMPARATOR
Intervention: Topotecan alone (1.25 mg/m2 intravenously on days 1 through 5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topotecan with berzosertib (210 mg/m2 intravenously on days 2 and 5)
Number of subjects: 60
Study: 37824145

Group type: EXPERIMENTAL
Intervention: Video tutorials on managing common symptoms in acutely ill children and when to seek medical help.
Number of subjects: 4686

Group type: EXPERIMENTAL
Intervention: Video tutorials
Number of subjects: 4686

Group type: COMPARATOR
Intervention: Telephone triage by a nurse or physician (control)
Number of subjects: 4686
Study: 37824152

Group type: EXPERIMENTAL
Intervention: Small-volume tubes
Number of subjects: 21201

Group type: COMPARATOR
Intervention: Standard-volume tubes
Number of subjects: 21201
Study: 37824155

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate (3 pools, 6-g fibrinogen equivalent) administered within 90 minutes of randomization and 3 hours of injury, in addition to standard care.
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Standard care (local major hemorrhage protocol).
Number of subjects: 1604

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate group.
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Standard care group.
Number of subjects: 1604
Study: 37824188

Group type: EXPERIMENTAL
Intervention: Real-time seat interface pressure mapping feedback
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Standard PI prevention education + Real-time seat interface pressure mapping feedback
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard PI prevention education
Number of subjects: 23
Study: 37824197

Group type: EXPERIMENTAL
Intervention: Cognitive test scores (Montreal Cognitive Assessment, Trail Making Test, Digit Symbol Substitution Test, forward and backward digit span testing)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Depression, stress, and anxiety screening
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum levels of biomarkers (SAA, Hcy, S100B, BDNF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 100
Study: 37824257

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 161
Study: 37824436

Group type: EXPERIMENTAL
Intervention: Dural puncture epidural (DPE) technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional epidural (EPL) technique
Number of subjects: 100
Study: 37824754

Group type: EXPERIMENTAL
Intervention: Art Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study: 37826937

Group type: EXPERIMENTAL
Intervention: 45 mg caffeine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 120 mg caffeine
Number of subjects: 45

Group type: COMPARATOR
Intervention: No caffeine
Number of subjects: 45
Study: 37826992

Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet (WD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fatty acid-matched diet devoid of walnuts (WFMD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diet where oleic acid replaces alpha-linolenic acid (ORAD)
Number of subjects: 35
Study: 37827268

Group type: EXPERIMENTAL
Intervention: Cabergoline (1 mg once on postpartum day 1 or 0.25 mg twice a day for 2 days)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pyridoxine (200 mg 3 times a day for 7 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pyridoxine
Number of subjects: 88
Study: 37827280

Group type: EXPERIMENTAL
Intervention: Prostate (bed) only radiotherapy (PBRT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Whole pelvis radiotherapy (WPRT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline α-diversity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metabolic fingerprint
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiation dose and treatment volume
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Toxicity risk stratification tools
Number of subjects: 50
Study: 37827557

Group type: EXPERIMENTAL
Intervention: UK HFpEF Registry
Number of subjects: 0
Study: 37827573

Group type: EXPERIMENTAL
Intervention: Face masks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No face masks
Number of subjects: 0
Study: 37827738

Group type: EXPERIMENTAL
Intervention: Questionable health behaviours assessment
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Psychological predictors assessment
Number of subjects: 1043
Study: 37827744

Group type: EXPERIMENTAL
Intervention: Patient-led home-based surveillance after curative CRC treatment.
Number of subjects: 0
Study: 37828033

Group type: EXPERIMENTAL
Intervention: Sintilimab (anti-PD-1) at doses of 1, 3, and 10 mg/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sintilimab (anti-PD-1)
Number of subjects: 29
Study: 37828034

Group type: EXPERIMENTAL
Intervention: ZSP1601 50 mg once daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ZSP1601 50 mg twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ZSP1601 100 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 37828071

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus severity and treatment regimen (oral medication vs insulin vs both oral + insulin)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Metabolic control reflected by HbA1c levels
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: LDL < 100 mg/dl
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: Use of statins
Number of subjects: 881

Group type: EXPERIMENTAL
Intervention: HbA1c ≤ 6.5
Number of subjects: 881
Study: 37828470

Group type: EXPERIMENTAL
Intervention: Clinical assessment, chest X-ray, and comprehensive lung function assessment at treatment completion and again six and 12 months later.
Number of subjects: 80
Study: 37828487

Group type: EXPERIMENTAL
Intervention: Music Breathing program (6 weeks, includes music listening and mindful breathing)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Mental Health Education Programme (6 weeks)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Music Breathing program
Number of subjects: 290

Group type: COMPARATOR
Intervention: Mental Health Education Programme
Number of subjects: 290
Study: 37828493

Group type: EXPERIMENTAL
Intervention: Moderate or severe unipolar depressive episode with at least passive suicidal thoughts
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Suicidality assessment using the Sheehan-Suicide Tracking Scale (S-STS)
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Exploratory objectives regarding suicidality
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Structured assessments of factors influencing self-injurious behavior
Number of subjects: 4500
Study: 37828503

Group type: EXPERIMENTAL
Intervention: Lower parent income
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Medicaid status
Number of subjects: 452

Group type: COMPARATOR
Intervention: Child delay discounting
Number of subjects: 452
Study: 37828564

Group type: EXPERIMENTAL
Intervention: Group Physical Therapy Program for Knee OA (Group PT) with tailored, high-touch support (enREP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Group Physical Therapy Program for Knee OA (Group PT) with standard, low-touch support (REP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Implementation outcomes (penetration, adoption, fidelity)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Staffing and labor costs
Number of subjects: 16
Study: 37828585

Group type: EXPERIMENTAL
Intervention: 3 M™ Coban™ elastic bandage for 48 h
Number of subjects: 360

Group type: COMPARATOR
Intervention: 3 M™ Coban™ elastic bandage for the first 24 h and then a class II compression full-length stocking (23-32 mm Hg) for 1 week
Number of subjects: 360
Study: 37828596

Group type: EXPERIMENTAL
Intervention: Text message reminder (TMR)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: TMR plus MI
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1180
Study: 37828618

Group type: EXPERIMENTAL
Intervention: Enhanced therapy (personalized treatment approach including pressure-optimized custom-made footwear, at-home daily foot temperature monitoring, structured education)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 37829600

Group type: EXPERIMENTAL
Intervention: Pfannenstiel skin incision adjusted according to the fetal head's occipitofrontal diameter (OFD)
Number of subjects: 114
Study: 37829689

Group type: EXPERIMENTAL
Intervention: Radial artery grafts (RA-CABG)
Number of subjects: 370
Study: 37829712

Group type: EXPERIMENTAL
Intervention: Exercise intervention (25 supervised endurance exercise sessions with moderate or high intensity for 8 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 62
Study: 37830208

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 37830268

Group type: EXPERIMENTAL
Intervention: CURE (Circumferential URE)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: RURE (Radial URE)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: CURE and RURE
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: UREs (CURE and RURE)
Number of subjects: 450
Study: 37830329

Group type: EXPERIMENTAL
Intervention: Real-time feedback on CPR performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback on CPR performance
Number of subjects: 0
Study: 37830338

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise Training (MIT) for 5 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT) for 4 months after 1 month of MIT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37830342

Group type: EXPERIMENTAL
Intervention: Tenecteplase, 0.4 mg/kg
Number of subjects: 483

Group type: COMPARATOR
Intervention: Alteplase, 0.9 mg/kg
Number of subjects: 483
Study: 37830344

Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 13815

Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 13815
Study: 37830451

Group type: EXPERIMENTAL
Intervention: Intervention group (RRMS patients experiencing relapses)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Relapse severity (associated factor)
Number of subjects: 1008
Study: 37830579

Group type: EXPERIMENTAL
Intervention: Mitazalimab (600 µg/kg and 900 µg/kg administered intravenously)
Number of subjects: 0
Study: 37830895

Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis (TM)
Number of subjects: 136742

Group type: COMPARATOR
Intervention: Digital mammography (DM)
Number of subjects: 136742

Group type: EXPERIMENTAL
Intervention: Quality control (QC) testing
Number of subjects: 136742
Study: 37830908

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine
Number of subjects: 439
Study: 37830944

Group type: EXPERIMENTAL
Intervention: Local resection (LR)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Radical resection (RR)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 183
Study: 37831046

Group type: EXPERIMENTAL
Intervention: HeartMate3 LVAD
Number of subjects: 2200
Study: 37831045

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 8232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8232
Study: 37831074

Group type: EXPERIMENTAL
Intervention: Continuous anti-IL-6R therapy
Number of subjects: 3
Study: 37831125

Group type: EXPERIMENTAL
Intervention: Intake reminder
Number of subjects: 84
Study: 37831212

Group type: EXPERIMENTAL
Intervention: DEEP-guided ablation
Number of subjects: 40

Group type: COMPARATOR
Intervention: non-DEEP (fixed-substrate-guided) ablation
Number of subjects: 40
Study: 37831378

Group type: EXPERIMENTAL
Intervention: Stimpod electromyograph
Number of subjects: 23
Study: 37831433

Group type: EXPERIMENTAL
Intervention: New prognostic model based on four variables: past deterioration, neutrophil proportion > 70%, Na < 128 mmol/L, and vasopressor use.
Number of subjects: 316

Group type: COMPARATOR
Intervention: Conventional prognostic models.
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Not applicable (no specific intervention mentioned).
Number of subjects: 316
Study: 37831448

Group type: EXPERIMENTAL
Intervention: HA-VTE prognostic model with pediatric hematologist review
Number of subjects: 17427

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis recommendations
Number of subjects: 17427

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 17427

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17427
Study: 37831485

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention focusing on PrEP use and concomitant stimulant use or CAS
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention with financial incentives for documented evidence of PrEP clinical evaluation and filling a PrEP prescription
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Second-stage intervention (MI+CM or CM+MI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Assessments only (control group)
Number of subjects: 70
Study: 37831490

Group type: EXPERIMENTAL
Intervention: Woebot (8-week digital mental health intervention)
Number of subjects: 202
Study: 37831494

Group type: EXPERIMENTAL
Intervention: Transauricular vagus nerve stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study: 37831492

Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wellness App (WA)
Number of subjects: 80
Study: 37831493

Group type: EXPERIMENTAL
Intervention: Managing Stress
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Basics
Number of subjects: 163

Group type: COMPARATOR
Intervention: Breathing exercises
Number of subjects: 163

Group type: COMPARATOR
Intervention: Audiobook (active control)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 163
Study: 37831682

Group type: EXPERIMENTAL
Intervention: Vibration-Controlled Transient Elastography (VCTE)
Number of subjects: 2866

Group type: EXPERIMENTAL
Intervention: Controlled Attenuation Parameter (CAP)
Number of subjects: 2866
Study: 37831737

Group type: EXPERIMENTAL
Intervention: TauroPace
Number of subjects: 631

Group type: COMPARATOR
Intervention: H2O2
Number of subjects: 631
Study: 37831815

Group type: EXPERIMENTAL
Intervention: Platelet count decrease by ≥ 25% from day 1 to day 3
Number of subjects: 249

Group type: COMPARATOR
Intervention: Baseline platelet count
Number of subjects: 249
Study: 37831917

Group type: EXPERIMENTAL
Intervention: Labor Dance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study: 37831941

Group type: EXPERIMENTAL
Intervention: HRF (OCT+/CFP-) extent
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: HPA extent
Number of subjects: 140
Study: 37832036

Group type: EXPERIMENTAL
Intervention: Genomic analysis of Cryptosporidium parvum isolates from Bangladeshi infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genomic analysis of Cryptosporidium parvum isolates from the United Kingdom
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human isolates from both locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic diversity of C. parvum
Number of subjects: 0
Study: 37832128

Group type: EXPERIMENTAL
Intervention: Neutral Position (NP)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Head Rotated
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Head Rotated with Arm Hyperabducted
Number of subjects: 8

Group type: COMPARATOR
Intervention: Head Rotated (ipsilateral or contralateral)
Number of subjects: 8
Study: 37832323

Group type: EXPERIMENTAL
Intervention: Therapist-guided in-session exposure with minimally-guided exposure at home (TGE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Parent-guided out-session homework (PGE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Minimally-guided exposure (MGE)
Number of subjects: 55